Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 25 of 25 publications.

Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928

Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Davis KL, Ubieto A, Nagar S, Zhang AJ, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. A retrospective cohort study of treatment outcomes of adult patients with relapsed or Refractory Follicular Lymphoma (ReCORD-FL). Hemasphere. 2022 Jun 21;6(7):e745. doi: 10.1097/HS9.0000000000000745

Fortuny J, Plana E, Kaye JA. Serum lipid trajectories in the years before a lymphoma diagnosis. Leuk Lymphoma. 2022 Feb;63(2):291-303. doi: 10.1080/10428194.2021.1992618

Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021 Jun;62(6):1325-34. doi: 10.1080/10428194.2021.1919662

Levy C, Bell T, Lyall M, Mamolo C, Neuhof A, Crawford R, Heyes A. The patient experience of multiple myeloma: symptoms and health-related quality of life. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):789.

Crawford R, Bell T, Levy C, Mamolo C, Lyall M, Neuhof A, Heyes A. The impact of COVID-19 on patient disease experience: insights from social media posts contributed by patients with multiple myeloma. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2).

Kortum KM, Nagar SP, Singh E, Davis KL, Lin PL. A multinational chart review of real-world treatment patterns and clinical outcomes in patients with relapsed/refractory multiple myeloma. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):466-7.

Lyall M, Heyes A, Bell T, Mamolo C, Neuhof A, Levy C, Crawford R. Multiple myeloma treatment decisions from the patient perspective. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):788.

Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza VK, Weisel K. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leuk Lymphoma. 2020 Mar;61(3):668-79. doi: 10.1080/10428194.2019.1683736

Purser M, Gallagher M, Mladsi D, Weber JM, Andermariam B, Kaye JA, Chawla A. Development of key criteria for an economic model for a potentially curative one-time treatment for sickle cell disease and evaluation of published models with respect to these criteria. Hemasphere. 2020;p.1098-9.

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Odom D, Gnanasakthy A, Suryanarayan K, Cain L, Romanus D, Rajkumar SV, Dimopoulos MA. Health-related quality of life (HRQOL) outcomes of oral ixazombi maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed mulitple myeloma (NDMM) from TOURMALINE-MM3. Poster presented at the 24th Congress of the European Hematology Association; June 2019. Amsterdam, The Netherlands. [abstract] Hemasphere. 2019 Jun; 3:266-7.

Goyal RK, Nagar SP, Kabadi SM, Kaye JA, Seal B, Mato AR. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2019 Apr;60(4):955-63. doi: 10.1080/10428194.2018.1509320

Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD, Dawson KL, Reid E. Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017 Apr;58(4):809-15.

Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621

Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma. 2015 May;56(5):1295-302. doi: 10.3109/10428194.2014.953144

Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590

Francois C, Danchenko N, Williams VS, Nelson LM, Williams NJ, Yarr SR, DiBenedetti DB, Lancon C. Psychometric evaluation of the depression and family functioning scale (DFFS). Poster presented at the Second Meeting on Patient Reported Outcomes and Person Centered Care in Mental Health – Diagnosis, Prevention and Treatment in Mental Health: Effectiveness and Comparative Effectiveness; September 26, 2014. Washington, DC. [abstract] J Ment Health Policy Econ. 2014 Sep; 17(Suppl 1):S5-6.

DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459

Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Course of pain and outcomes of depression. Results from a three - month, prospective, observational study from Asia. Poster presented at the Eleventh Workshop on Costs and Assessment in Psychiatry; March 2013. Venice, Italy. [abstract] J Ment Health Policy Econ. 2013 Mar; 16(Suppl 1):S27-8.

Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Does the presence of co-morbid conditions explain the impact of pain in depression outcomes? Poster presented at the Eleventh Workshop on Costs and Assessment in Psychiatry; March 2013. Venice, Italy. [abstract] J Ment Health Policy Econ. 2013 Mar; 16(1):S27.

Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.

Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.

Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Dec;49(12):2298-307. doi: 10.1080/10428190802517732

Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.

López MV, Rivero E, Serra C, Campo M, Raurich M, Bonfill X. Health survey in health care professionals in Barcelona. Arch Prev Riesgos Laborales. 1998;1(2):55-62.